A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain

NCT ID: NCT01165281

Last Updated: 2017-07-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 343 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-08-31
• Study Completion Date: 2012-08-31

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of R331333 (referred to as JNS024 Extended-Release (ER) or CG5503) compared with an active comparator (oxycodone Controlled Release (CR)) in Japanese and Korean patients with chronic, malignant, tumor-related cancer pain.

Detailed Description

This is a randomized (study drug assigned by chance), double-blind (neither the patient nor the study staff will know the identity of the study drug assigned to each patient), multicenter study to evaluate the safety and efficacy of orally (by mouth) administered R331333 (referred to as JNS024 extended release [ER] capsules or CG5503) in dosages of 25 mg to 200 mg twice daily compared with orally administered capsules of oxycodone controlled release (CR) in dosages of 5 mg to 40 mg twice daily over 4 weeks in Japanese and Korean patients with moderate to severe chronic malignant tumor-related cancer pain who require around-the-clock opioid therapy (treatment with narcotic analgesics or pain relievers) and are dissatisfied with the pain relief they are experiencing from current treatment. The active control, oxycodone CR, is being used in this study because it is an opioid analgesic approved for the treatment of moderate to severe pain. Approximately 212 Japanese patients and approximately 100 Korean patients who meet screening criteria for the study will be enrolled in the study and will enter the titration period of the study where they will receive a starting dosage of either JNS024 ER 25 mg twice daily or oxycodone CR 5 mg twice daily. The dose of study drug for each patient will be titrated (increased) to the optimal dose until sufficient analgesia (pain relief) is achieved (ie, up to a maximum dose of JNS024 ER 200 mg twice daily or Oxycodone CR 40 mg twice daily). When the dosage of study drug is increased, the safety will be confirmed at the study visit or by telephone on the day after the dose is increased. Once an optimal dose of study drug is determined, the patient will continue to receive that dose during the maintenance period in the study. Patients will participate in the study for total of approximately 6 weeks; during this time patients will receive study drug for 4 weeks (titration and maintenance periods combined). During the study, if a patient experiences breakthrough pain (pain that occurs for short periods of time between doses of study drug), treatment with rescue medication (morphine immediate release [IR] 5 mg) will be given. In addition, patients will be allowed to continue to take stable doses of non-opioid analgesics (non-narcotic pain medications for mild to moderate pain) that they were taking at the time of study entry and may reduce the dosage or discontinue their use during the study. During the study, blood samples will be collected from patients at protocol-specified time points to determine the concentration of study drug after administration. The safety of patients will be monitored during the study by evaluating adverse events and findings from clinical laboratory tests, physical examinations, vital signs measurements, and electrocardiogram (ECG) measurements reported. The primary outcome measure in the study will be the change from baseline to the last 3 days of study drug administration in the average pain intensity score using an 11 point numerical rating scale (NRS). Patients will receive R331333 (referred to as JNS024 ER or CG5503) by mouth with or without food at a starting dose of 25 mg twice daily to be increased if necessary to a maximum dose of 200 mg twice daily for a total of 4 weeks (titration and maintenance periods combined) OR double-blind oxycodone CR by mouth with or without food at a starting dose of 5 mg twice daily to be increased if necessary to a maximum dose of 40 mg twice daily for a total of 4 weeks.

Conditions

Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

001

R331333 (referred to as JNS024 ER or CG5503) One 25 mg to 200 mg capsule twice daily for 4 weeks.

Group Type: EXPERIMENTAL

R331333 (referred to as JNS024 ER or CG5503)

Intervention Type: DRUG

One 25 mg to 200 mg capsule twice daily for 4 weeks.

002

Oxycodone CR One 5 mg to 40 mg capsule twice daily for 4 weeks.

Group Type: ACTIVE_COMPARATOR

Oxycodone CR

Intervention Type: DRUG

One 5 mg to 40 mg capsule twice daily for 4 weeks.

Interventions

Oxycodone CR

One 5 mg to 40 mg capsule twice daily for 4 weeks.

Intervention Type: DRUG

R331333 (referred to as JNS024 ER or CG5503)

One 25 mg to 200 mg capsule twice daily for 4 weeks.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Documented clinical diagnosis of any type of cancer
• Diagnosis of chronic malignant tumor-related cancer pain with an average score for pain intensity in the past 24 hours of >=4 on the 11-point numerical rating scale (NRS) on the day of randomization (Day -1)
• Have not received treatment with opioid analgesics within 28 days before screening (Note: codeine phosphate [<=60 mg/d] or dihydrocodeine phosphate [<=30 mg/d] for antitussive use are allowed)
• Dissatisfied with pain relief by the current treatment and for whom the investigator or designee judges that treatment with opioid analgesics is required

Exclusion Criteria

• Have complicated with uncontrolled/clinically significant arrhythmia
• Have previous or concurrent presence of any disease which may develop increased intracranial pressure, disturbance of consciousness, lethargy, or respiratory problems such as traumatic encephalopathy with cerebral contusion, intracranial hematoma, disturbance of consciousness, brain tumor, cerebral infarction, transient ischemic attack, epilepsy or convulsive diseases
• Have history of alcohol and/or drug abuse
• Have any disease for which opioids are contraindicated such as serious respiratory depression of serious chronic obstructive pulmonary disease, bronchial asthma attack, cardiac failure secondary to chronic pulmonary disease, paralytic ileus, status epileptics, tetanus, strychnine poisoning, acute alcohol poisoning, hypersensitivity to opium alkaloid, hemorrhagic colitis, or bacterial diarrhea

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 99 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Janssen Research & Development, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Janssen Research & Development, LLC Clinical Trial

Role: STUDY_DIRECTOR

Janssen Research & Development, LLC

Locations

Chiba, , Japan

Fukui, , Japan

Fukushima, , Japan

Fukuyama, , Japan

Fushimi, , Japan

Hamamatsu, , Japan

Hirosaki, , Japan

Hitachi, , Japan

Itami, , Japan

Iwakuni, , Japan

Izumo, , Japan

Kamogawa, , Japan

Kanuma, , Japan

Kobe, , Japan

Kumagaya, , Japan

Kumamoto, , Japan

Kure, , Japan

Kyoto, , Japan

Matsumoto, , Japan

Matsusaka, , Japan

Miyazaki, , Japan

Nagoya, , Japan

Natori, , Japan

Niigata, , Japan

Ogōri, , Japan

Ohta, , Japan

Okayama, , Japan

Osaka, , Japan

Saga, , Japan

Saku, , Japan

Sapporo, , Japan

Sendai, , Japan

Sunto, , Japan

Takarazuka, , Japan

Takasaki, , Japan

Tokyo, , Japan

Tomakomai, , Japan

Toyama, , Japan

Toyonaka, , Japan

Ube, , Japan

Yamagata, , Japan

Yamanashi, , Japan

Yokohama, , Japan

Busan, , South Korea

Chungcheongbuk-Do, , South Korea

Daegu, , South Korea

Deajun, , South Korea

Gyeonggi-do, , South Korea

Incheon, , South Korea

Jinju, , South Korea

Seoul, , South Korea

Suwon, , South Korea

Countries

Japan; South Korea

References

Imanaka K, Tominaga Y, Etropolski M, van Hove I, Ohsaka M, Wanibe M, Hirose K, Matsumura T. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Curr Med Res Opin. 2013 Oct;29(10):1399-409. doi: 10.1185/03007995.2013.831816. Epub 2013 Aug 23.

Reference Type: DERIVED

PMID: 23937387 (View on PubMed)

Other Identifiers

JNS024ER-KAJ-C02

Identifier Type: OTHER

Identifier Source: secondary_id

CR017188

Identifier Type: -

Identifier Source: org_study_id